FILE - A supermoon rises through clouds over the skyline of lower Manhattan, Aug. 1, 2023, as seen from West Orange, N.J. Stargazers are in for a double treat on Wednesday night, Aug. 30: a rare blue supermoon with Saturn peeking from behind. The cosmic curtain rises Wednesday night with the second full moon of August, the reason it’s considered blue. It’s dubbed a supermoon because it’s closer to Earth than usual, appearing especially big and bright. (AP Photo/Seth Wenig, File)
By Marcia Dunn
Stargazers are in for a double treat on Aug. 30: a rare blue supermoon with Saturn peeking from behind.
The cosmic curtain rises Wednesday night with the second full moon of the month, the reason it’s considered blue. It’s dubbed a supermoon because it’s closer to Earth than usual, appearing especially big and bright.
This will be the closest full moon of the year, just 222,043 miles (357,344 kilometers) or so away. That’s more than 100 miles (160 kilometers) closer than the Aug. 1 supermoon.
As a bonus, Saturn will be visible as a bright point 5 degrees to the upper right of the moon at sunset in the east-southeastern sky, according to NASA. The ringed planet will appear to circle clockwise around the moon as the night wears on.
If you missed the month’s first spectacle, better catch this one. There won’t be another blue supermoon until 2037, according to Italian astronomer Gianluca Masi, founder of the Virtual Telescope Project.
Clouds spoiled Masi's attempt to livestream the supermoon rising earlier this month. He’s hoping for clearer skies this time so he can capture the blue supermoon shining above St. Peter’s Basilica at the Vatican.
Weather permitting, observers don’t need binoculars or telescopes — “just their own eyes." said Masi.
“I’m always excited to admire the beauty of the night sky,” he said, especially when it features a blue supermoon.
The first supermoon of 2023 was in July. The fourth and last will be in September.
An FDA panel has recommended the low-dose Pfizer vaccine for kids ages five to 11. The recommendation now cues up the FDA to authorize the vaccine. Next week, the CDC will consider its own authorization. Once signed off by the CDC, the Pfizer vaccine can be administered in children immediately. Dr. Christina Johns, Senior Medical Advisor at PM Pediatrics, joined Cheddar's Search for a Cure.
Dr. Vivek Cherin, Internal Medicine Physician at Amita Health, joined Cheddar's Search for a Cure to break down what we need to know about eligibility and availability of COVID-19 vaccine boosters.
World leaders will converge this weekend at the 2021 G20 Summit in Rome and the UN COP26 conference in Glasgow with the climate crisis on the agenda. Lord Adair Turner, chair of the Energy Transitions Commission, joined Cheddar to discuss what people can expect to come out of the climate-focused conferences. Turner also noted that one of the biggest hurdles for the attending nations will be coming to a uniform decision on expanding on the Paris Climate Accord goals that have become insufficient to prevent global warming by 1.5 degrees celsius.
Nicole Lambert, President at Myriad Genetics joins ChedHER to discuss how to expand access to genetic testing for all women, and how her experience as a 'pre-vivor' motivates her role in the industry.
Carlo and Baker cover Facebook's big rebrand, the latest on Biden's economic agenda and more. Plus, ranking the best Halloween candy and the worst couple's costumes.
Proptech startup Juno recently raised $20 million in a Series A funding round. The company says the funds will be used to further its mission of building sustainable and affordable apartment buildings across the United States. Juno Co-Founder and CEO Jonathan Sherr joined Cheddar News' Closing Bell to discuss.
Stacey Stevens, President of iCAD, joins 'Cheddar Innovates' to discuss how 'Profound A.I. Risk' works as a short-term breast cancer risk estimation for women.
On this episode of 'Cheddar Innovates': President of iCAD breaks down how its technology is being used as a short-term breast cancer risk estimation for women; A look at Curiosity Stream's 'The Science of Thrills.'
Pharmaceutical company Merck has announced that it will share the formula of its COVID-19 pill with poor countries free of charge. The company still intends to charge wealthier nations leaving the end cost at more than $700 per five-day treatment course.
Dems race for a deal on President Biden's economic agenda ahead of his big foreign trip. What to make of the latest threat assessment in Afghanistan. Plus, the meme cryptocurrency of the moment that's now worth more than many Fortune 500 companies.
